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Slope of the Anterior 
Mitral Valve Leaflet:
A New Measurement of Left 
Ventricular Unloading for Left Ventricular 
Assist Devices and Systolic Dysfunction
Left ventricular assist device (LVAD)-supported patients are evaluated routinely with use of 
transthoracic echocardiography. Values of left ventricular unloading in this unique patient 
population are needed to evaluate LVAD function and assist in patient follow-up.
We introduce a new M-mode measurement, the slope of the anterior mitral valve leaf-
let (SLAM), and compare its efficacy with that of other standard echocardiographically 
evaluated values for left ventricular loading, including E/ec and pulmonary artery systolic 
pressures. Average SLAM values were determined retrospectively for cohorts of random, 
non-LVAD patients with moderately to severely impaired left ventricular ejection fraction 
(LVEF) (<0.35, n=60). In addition, pre- and post-LVAD implantation echocardiographic im-
ages of 81 patients were reviewed.
The average SLAM in patients with an LVEF <0.35 was 11.6 cm/s (95% confidence 
interval, 10.4–12.8); SLAM had a moderately strong correlation with E/ec in these patients. 
Implantation of LVADs significantly increased the SLAM from 7.3 r 2.44 to 14.7 r 5.01 
cm/s (n=42, P <0.0001). The LVAD-supported patients readmitted for exacerbation of con-
gestive heart failure exhibited decreased SLAM from 12 r 3.93 to 7.3 r 3.5 cm/s (n=6, 
P=0.041). In addition, a cutpoint of 10 cm/s distinguished random patients with LVEF 
<0.35 from those in end-stage congestive heart failure (pre-LVAD) with an 88% sensitivity 
and a 55% specificity.
Evaluating ventricular unloading in LVAD patients remains challenging. Our novel M-
mode value correlates with echocardiographic values of left ventricular filling in patients 
with moderate-to-severe systolic function and dynamically improves with the ventricular 
unloading of an LVAD. (Tex Heart Inst J 2014;41(3):262-72)
T herapy with an implanted continuous-flow left ventricular assist device (CF-LVAD) has improved survival rates and quality of life in patients with end-stage heart failure by increasing cardiac output and decreasing left ventricular 
(LV) preload.1-3 In non-LVAD–supported patients with heart failure, multiple trans-
thoracic echocardiographic (TTE) methods exist for evaluating LV filling pressures, 
including chamber dimensions, mitral valve inflow Doppler measurements, pulmo-
nary venous Doppler measurements, and tissue Doppler velocities.4-6 In patients with 
nonphysiologic unloading of the LV by a CF-LVAD, acquisition and interpretation 
of the Doppler and echocardiographic images required for many of these accepted 
methods might be challenging. Even in circumstances in which accurate Doppler 
evaluation is possible, some studies in CF-LVAD patients have revealed that, although 
E/ec ratio decreases after LVAD implantation, it correlates poorly with invasive mea-
surements of pulmonary capillary wedge pressure (PCWP).7,8 Other guidelines are 
therefore needed to supplement current knowledge toward evaluating LV unloading 
and clinical status in CF-LVAD–supported patients.
 The mitral valve is a fast-moving structure, the motion of which is best detected 
with the superior temporal resolution of M-mode echocardiography in the parasternal 
views.9 In the presence of elevated filling pressures, the anterior mitral leaflet tracing 
in M-mode displays gradual closure after the peak of the A-wave in cardiac diastole, 
as compared with brisk closure in patients with normal filling pressures.9 In extreme 
cases, this closure process slows to the point where there is a recognizable “B-bump” 
after atrial contraction, which for more than 40 years has been known to correlate with 
significantly elevated LV end-diastolic pressure (LVEDP)— greater than 20 mmHg.10 
Until now, the slope of the anterior mitral leaflet (SLAM) in end-diastole has never 
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been measured or quantified. In the present study, we 
examined the clinical usefulness of this phenomenon by 
evaluating SLAM in randomly selected patients with 
systolic heart failure, and in LVAD-implanted patients 
before and after LVAD implantation. We hypothesized 
that the SLAM would indicate relative LV filling pres-
sures, and that it would increase in patients with end-
stage heart failure after CF-LVAD support.
Patients and Methods
Our echocardiographic database was queried randomly 
for 60 non-intensive care unit patients with moderate-to-
severe systolic dysfunction (LV ejection fraction [LVEF], 
<0.35) on studies performed from January through 
March 2010. In addition, the clinical records and echo-
cardiograms of 81 adult recipients of the HeartMate II® 
LVAD (Thoratec Corporation; Pleasanton, Calif ) from 
January 2007 through December 2010 were evaluated 
in a single-center, retrospective review. The retrospective 
study was approved by the institutional review board of 
the Washington University School of Medicine.
Echocardiographic Data
We reviewed parasternal and apical views, including 
2-dimensional (2D), Doppler, and M-mode data ob-
tained with use of the iE33 (Koninklijke Philips N.V.; 
Best, The Netherlands) or the GE Vivid 7® ultrasound 
system (GE VingMed Ultrasound AS; Horten, Nor-
way). Doppler and 2D measurements included: LVEF 
by means of the Simpson method, E point-septal sepa-
ration (EPSS) in triplicate, LV end-diastolic and end-
systolic diameters, peak early (E) transmitral filling ve-
locity in diastole, early tissue septal and lateral annular 
velocities (Ec), pulmonary artery pressure estimates by 
tricuspid regurgitation velocity and inferior vena cava 
size, and right ventricular outflow tract (RVOT) vol-
ume thickness index (VTI).4,11,12
 The SLAM closure after the atrial phase of LV dia-
stolic f illing was obtained from 2D-guided M-mode 
TTE images of the mitral valve in parasternal views 
obtained at either a 66-mm/s or 100-mm/s sweep 
speed. With use of ProSolv® software (FUJIFILM Medi-
cal USA, Inc.; Stamford, Conn), the slope was calcu-
lated in cm/s between a point of inflection at which the 
anterior mitral valve leaflet begins a downward descent 
and another point at which it meets the posterior mitral 
valve leaflet, closing the mitral valve. Figure 1 shows an 
illustration of the methodology and actual image mea-
surements. The slope was obtained at the underside of 
the valve for thickened anterior mitral valve leaflets, at 
which the image contrast between the valve space and 
valve tissue is greatest. If the downward descent of the A 
wave contained a “B-bump,” the slope remained calcu-
lated from the inflection of the A-wave descent to mitral 
valve closure. We included only patients for whom at 
least 3 cardiac cycles were available, in order to gener-
ate a mean SLAM for each patient’s study. Our LVAD 
analysis of SLAM was obtained only on those patients 
for whom we had paired before- and after-implantation 
data. After-implantation data were obtained in patients 
in the ambulatory setting or who were readmitted for 
reasons other than exacerbation of congestive heart fail-
ure (CHF) . Patients were excluded for atrial fibrillation 
or f lutter, mechanical mitral valves, excessive artifact 
from bioprosthetic valve struts, and poor image qual-
ity that precluded slope analysis. The slope is negative; 
however, for clarity, the slope in this article is expressed 
as an absolute value with SD, obviating the need for a 
preceding negative sign (–).
Serum Pro-Brain Natriuretic  
Peptide Measurement
Serum pro-brain natriuretic peptide (BNP) levels (pg/
mL) were obtained retrospectively for LVAD patients 
during the patients’ hospital admission before LVAD 
implantation, and either before discharge from the hos-
pital or at a follow-up hospital admission or outpatient 
appointment. All samples were analyzed by the institu-
tional core laboratory.
Diuretic Requirement
The diuretic requirement for each patient was collected 
before and after LVAD surgery. Furosemide intravenous 
(IV)-equivalent dosing was calculated in such a manner 
that 40 mg of IV furosemide was equivalent to 80 mg 
of oral furosemide, 20 mg of IV torsemide, or 1 mg of 
IV bumetanide.13-16
SLAM in the Presence of  
Acute Heart Failure Exacerbation
We next sought to examine the usefulness of SLAM as 
an indicator of clinical status in CF-LVAD–supported 
patients. Through detailed chart reviews, we analyzed 
the SLAM of patients readmitted for CHF during the 
study period who had suitable echocardiographic im-
ages before LVAD implantation, after LVAD implanta-
tion in an ambulatory setting, and during the CHF re-
admission for analysis, according to discharge diagnosis.
Statistical Methods
All tests for significance were conducted at the 5% error 
rate (P=0.05). Analysis was conducted with use of SAS 
software version 9.3 (SAS Institute Inc.; Cary, NC). 
Change in the M-mode slope from before LVAD im-
plantation to after-implantation and upon readmission 
for heart-failure symptoms was determined by means 
of a paired t test. Only LVAD patients for whom we 
had paired measurements and 3 cycles per condition 
were included in this part of the analysis. Reproduc-
ibility was analyzed for inter- and intraobserver reli-
ability by means of the intraclass correlation coefficient 
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(ICC) and the Bland-Altman method.17 Before-to-after 
LVAD changes for RVOT-VTI, BNP, diuretic require-
ment, pulmonary artery pressure, EPSS, and LV end-
diastolic and end-systolic diameters were calculated by 
means of the Student paired t tests. The correlation be-
tween PCWP and SLAM before LVAD implantation 
was examined by means of the Pearson correlation co-
efficient. The Fisher exact test was used for categorical 
variables in demographic categories.
 Patients with moderate-to-severe systolic dysfunction 
were combined with before- and after-LVAD patients, 
to examine differences in mean SLAM between each 
group. Analysis of covariance (ANCOVA) was conduct-
ed to adjust for age and sex. Group means and all paired 
comparisons were on the basis of model results. A cor-
rection for multiple comparison tests was applied. Two 
different ANCOVA models were built: one with LVAD 
pre-implant SLAM values and one with LVAD post-
implant SLAM values. Changes in SLAM and E/ec 
from post-LVAD status to readmission were evaluated 
by means of paired t tests. Only patients for whom we 
had post-implant and readmission data were included 
in this analysis.
 The ability of SLAM to distinguish accurately be-
tween groups was evaluated by means of the area under 
the receiver operating characteristic curve. Comparisons 
were made between random patients with an LVEF 
<0.35 and pre-LVAD patients. Sensitivity and specific-
ity were determined, and an optimal cutpoint was cho-
sen on the basis of the Youden index. The correlation 
between SLAM, E/ec, and LVEF values was examined 
by means of the Pearson correlation coefficient. Devia-
tion from linearity was examined by means of scatter 
plots and a regression model, including the quadratic 
term for E/ec.
Results
SLAM in Patients with Moderate-to-Severe 
Systolic Dysfunction
The SLAM, LVEF, and E/ec were f irst evaluated in 
cohorts of patients who had at least moderately im-
Fig. 1  Slope measurement methodology. A) The slope of the anterior mitral valve leaflet (SLAM) is measured at the point of inflection 
of the A-wave descent in diastole. B) Example of the SLAM measured in a patient with increased left ventricular end-diastolic pres-
sure, including the “B-bump.” C) Example of a steep SLAM. D) Two-dimensional–guided M-mode transthoracic echocardiogram of 
the mitral valve (parasternal long-axis view) at 66-mm/s sweep speed. The SLAM is identified in red. E) The SLAM measurement at the 
point of inflection, from the underside of the leaflet to the point of valve closure, as shown by the red line.
A B C
D E
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paired LVEF (<0.35). The median SLAM was 11.6 
r 5.27 cm/s for patients with LVEF <0.35 (Table I). 
Linear regression analysis revealed no signif icant cor-
relation between SLAM and LVEF. Figure 2A shows 
a representative M-mode TTE image of the SLAM in 
a patient with an LVEF <0.35, and Figure 2B shows a 
selected line for SLAM determination. To evaluate the 
correlation of SLAM with estimated f illing pressures 
in these patients, the ratios of early transmitral velocity 
(E) to the average of medial and lateral annular early 
myocardial tissue Doppler velocities (ec) were plotted 
against the SLAM values (Fig. 2C). The median E/ec 
of patients with moderate-to-severe LV dysfunction was 
16.3 r 7.74 and correlated significantly with the SLAM 
in a linear fashion (r= –0.473, P=0.0001) (Fig. 2C). 
Unsupported, randomly selected patients with mod-
erately to severely depressed LVEFs therefore display a 
correlation between SLAM and E/ec measurements, 
and E/ec is well validated in this population to correlate 
closely with LV filling pressures.5
Demographic Characteristics  
of the LVAD Study Population
We identif ied 81 LVAD patients who had undergone 
HeartMate II implantation at our institution. They 
were predominantly male (79%) and white (72%), 
with a median age of 53.8 r 13.05 years (Table II). 
Approximately one third had diabetes mellitus at the 
time of implantation, and the cause of heart failure was 
nonischemic cardiomyopathy in 54%. We were unable 
to obtain the SLAM for 39 of these patients because 
of atrial fibrillation (n=7), lack of before-implantation 
TTE studies (n=5), lack of after-implantation TTE 
studies (n=8), mechanical mitral valves (n=3), unin-
terpretable images of the mitral valve in 2D or M mode 
(n=7), and fewer than 3 cardiac cycles for the before- or 
after-LVAD windows (n=9).
TABLE I. Random Patients with LVEF <0.35
 Variable LVEF <0.35 (N=60)
Age (yr) 54.3 r 15.74
Male sex 32 (53)
LVEF 0.22 r 0.53
SLAM (cm/s) 11.6 r 5.27
E/ec ratio 16.2 r 7.74
Calculated PCWP (mmHg) 22 r 9.59
 
E = Early diastolic mitral velocity; ec = mitral annular tissue 
velocity; LVEF = left ventricular ejection fraction; PCWP = 
pulmonary capillary wedge pressure; SLAM = slope of the 
anterior mitral valve leaflet 
 






















Fig. 2  Slope of the anterior mitral leaflet (SLAM): LVEF <0.35 
and correlation with E/ec. A) M-mode transthoracic echocar-
diographic image of the mitral valve in a patient with a left ven-
tricular ejection fraction (LVEF) <0.35. B) One diastolic cycle of 
the same M-mode image of the mitral valve with the visualized 
SLAM. C) Plot of E/ec and SLAM in patients with an LVEF <0.35, 
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Echocardiographic and Laboratory Values 
Before and After LVAD Implantation
We next evaluated currently accepted echocardiograph-
ic and clinical values of heart failure in the CF-LVAD–
supported patient group both before and after LVAD 
implantation (Table III). Consistent with the medical 
literature,18,19 the LV end-diastolic and end-systolic di-
mensions and estimated pulmonary artery pressures de-
creased by approximately 20% to 30% after LVAD im-
plantation (P <0.001). The EPSS decreased an average 
of 28.5% (from 2.5 to 1.8 cm) after LVAD implantation 
(P <0.0001). The RVOT-VTI signif icantly increased 
after LVAD implantation (P <0.0001), which was simi-
lar to increases in prior studies.20 In addition, our patient 
population showed a reduction in BNP similar to that 
in other institutional populations after LVAD surgery, 
from an average of 1,715 to 305 pg/mL (P <0.0001).8 
Concomitant with a decrease in BNP, diuretic dosing 
(expressed as roughly equivalent to IV furosemide) de-
creased from approximately 70 mg/d to 22 mg/d, at a 
documented outpatient visit. These results indicate that, 
after LVAD implantation, our patients experienced an 
expected improvement in cardiac output and a decrease 
in congestion.
 We next sought to validate the SLAM value in the 
sicker group of CHF patients who later received an 
LVAD. Invasive hemodynamic data were available for 23 
patients before LVAD implantation within 48 hours of 
the TTE and SLAM measurement. The median before-
implantation PCWP was 26 r 5.9 mmHg. In these pa-
tients, the average SLAM was 7 cm/s, which was signifi-
cantly lower than the average SLAM in moderate-to-se-
vere native heart failure (SLAM, 11.6 cm/s; P d0.0001). 
Upon LVAD implantation, the E/ec value significantly 
decreased from 19.4 r 8.72 to 13.3 r 10.91 (P=0.0042), 
which was similar to a published observation in hemo-
dynamically stable outpatients.19 The before-LVAD E/ec 
ratio correlated significantly with the SLAM (r= –0.409, 
P=0.0119), although the after-LVAD E/ec did not (r= 
–0.249, P=0.1631). After LVAD implantation, the mean 
SLAM of patients increased in steepness from 7.3 r 2.44 
to 14.7 r 5.01 cm/s (n=42; P <0.0001) at a mean of 11 
months after implantation (range, 5 d–47 mo) (Fig. 3). 
Interobserver ICC values ranged from 0.864 to 0.932, 
and intraobserver ICC values ranged from 0.881 to 
0.908 (Table IV). The Bland-Altman graphs suggested 
few to no differences between observer measurements, 
and insignificant results were found upon testing for lin-
earity (P >0.2 in all) (Fig. 4). Taken together, the ICC 
and Bland-Altman analyses indicate that inter- and in-
traobservations are equally precise.
SLAM in LVAD Patients Admitted for 
Congestive Heart Failure Exacerbation
During the study period, 13 patients with CF-LVADs 
were readmitted for CHF exacerbation (Table V). Of 
TABLE II. Characteristics of the 81 Patients with LVADs
      Variable  Value
Age (yr) 53.8 r 13.05
Male sex 64 (79)
White 59 (73)
Black 22 (27)
Diabetes mellitus 26 (32)
Ischemic cardiomyopathy 37 (46)
 
LVADs = left ventricular assist devices 
 
Values are expressed as mean r SD or as number and 
percentage.
TABLE III. Comparison of Variables Before and After LVAD Implantation
            Variable N Before LVAD After LVAD P Value*
M-mode SLAM (cm/s) 42 7.3 r 2.44 14.7 r 5.01 <0.0001
RVOT-VTI (cm) 54 6.5 r 3.07 9.8 r 2.75 <0.0001
BNP (pg/mL) 45 1,758.2 r 1,286.17 350.4 r 245.4 <0.0001
PASP (mmHg) 48 53.4 r 14.21 33.4 r 10.13 <0.0001
EPSS (cm) 43 2.6 r 0.59 1.8 r 0.76 <0.0001
LVEDD (cm) 54 6.8 r 1 5.5 r 1.46 <0.0001
LVESD (cm) 54 6.1 r 0.96 5 r 1.45 <0.0001
Furosemide IV requirement (mg/d) 60 69.8 r 54.16 21.7 r 21.41 <0.0001
 
BNP = pro-brain natriuretic peptide; EPSS = E-point septal separation; IV = intravenous; LVAD = left ventricular assist device; 
LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter; PASP = pulmonary artery systolic 
pressure; RVOT-VTI = right ventricular outflow tract-volume thickness index; SLAM = slope of the anterior mitral valve leaflet 
 
*On the basis of paired t test 
 
Values are expressed as mean r SD. P <0.05 was considered statistically significant.
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these, 6 had correlative echocardiographic data before 
and after LVAD implantation and after LVAD im-
plantation with CHF-exacerbation symptoms with a 
SLAM value, and 7 had echocardiographic data in these 
3 conditions for E/ec. Comparison between echocar-
diograms obtained after LVAD placement without an 
admission diagnosis of CHF, and at readmission for a 
CHF exacerbation, revealed a signif icant decrease in 
SLAM from 12 r 3.93 to 7.3 r 3.5 (P=0.041). Figure 5 
shows representative findings in one patient who had a 
suspected pump thrombosis. The E/ec ratio of these 13 
patients displayed marked variability, and an increase in 
E/ec from 15.9 r 11.04 to 19.04 r 14.42 was not statisti-
cally significant (P=0.112).
Distinguishing between Systolic 
Dysfunction and Advanced Heart 
Failure (before LVAD Placement)
Finally, we sought to identify a cutoff SLAM value to 
distinguish between randomly selected systolic CHF pa-
tients with an LVEF <0.35 and advanced-CHF patients 
who needed LVAD support. After adjusting for age 
and sex, we found that the SLAM of the before-LVAD 
patients was significantly lower (7.1 cm/s; P <0.0001) 
than that of randomly selected patients with an LVEF 
<0.35 (Fig. 6A). A separate analysis of the after-LVAD 
implantation patients also yielded a significant differ-
ence in SLAM between patients after LVAD placement 
(14.5 cm/s; 95% CI, 13–16) and those with LVEF 
<0.35 (11.6 cm/s; 95% CI, 10.4–12.8) (P=0.008). A 
receiver operating characteristic analysis indicated that 
SLAM could distinguish before-LVAD patients in end-
stage heart failure from the randomly selected patients 
with an LVEF <0.35 at an area under the curve (AUC) 
of 0.7742 (95% CI, 0.6853–0.8631). An AUC of 1.0 
would suggest perfect accuracy, whereas an AUC of 0.5 
would indicate that SLAM is no better than chance 
(Fig. 6B). An optimal SLAM cutpoint of 10 cm/s, de-
termined by means of Youden index analysis, had an 
88% sensitivity and a 55% specificity at distinguish-
ing patients with end-stage CHF in the before-LVAD 
category from all patients with LVEF <0.35 (Table VI).
Fig. 3  Two-dimensional guided M-mode transthoracic echocardiograms show the mitral valve A) before left ventricular assist device 
(LVAD) implantation and B) a steeper descending slope of the anterior mitral valve leaflet (SLAM) after implantation. C) Graph shows 
raw SLAM data from 42 patients before LVAD implantation (7.3 r 2.44 cm/s) and after implantation (14.7 r 5.01 cm/s; P <0.0001).  














Before LVAD Aer LVAD
A B C
TABLE IV. Inter- and Intraobserver Agreement for Before- and After-LVAD Measurements of SLAM
 Bland-Altman Intraclass Correlation
 95% Limits
       Variable Bias Lower Upper P Value Coefficient 95% CI
Interobserver
Before 0.25 –1.66 2.18 0.24 0.932 (0.842–0.971)
After –1.03 –6.92 4.85 0.53 0.864 (0.709–0.939)
Intraobserver
Before –0.09 –1.63 1.45 0.3 0.881 (0.65–0.963)
After 0.79 –2.11 3.69 0.96 0.908 (0.721–0.972)
 
CI = confidence interval; LVAD = left ventricular assist device; SLAM = slope of the anterior mitral valve leaflet 
 
P <0.05 was considered statistically significant.
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Discussion
Noninvasive evaluation of LV filling values in LVAD-
supported patients is a vexing clinical problem. Con-
tinuous-flow LVADs unload the LV by pumping blood 
from the LV apex to the ascending aorta. The conse-
quences of apical surgical LVAD implantation and near-
pulseless LVAD-driven blood flow with variable output 
through the native aortic valve pose new challenges in 
evaluating circulatory hemodynamic status with use 
of noninvasive imaging. Currently accepted methods 
for evaluating LV filling pressures, such as E/ec, might 
at times be difficult to obtain or be unreliable because 
of an acoustic artifact consequent to positioning the 
transducer at the cardiac apex.20 In the present study, 





























































Fig. 4  Graphs, showing Bland-Altman plots of interobserver agreement A) before and B) after left ventricular assist device (LVAD) 
implantation, and intraobserver agreement C) before and D) after implantation, suggest few to no differences between observer  
measurements; insignificant results were found upon testing for linearity. P d0.05 was considered statistically significant. 
 
SLAM = slope of the anterior mitral valve leaflet
TABLE V. Comparison of 13 Patients after LVAD Implantation and at Hospital Readmission
Variable No. Pts. After LVAD Readmission LVAD P Value*
SLAM 6 12 r 3.93 7.3 r 3.5 0.0409
E/ec 7 15.9 r 11.04 19.04 r 14.42 0.1124
 
E = early diastolic mitral velocity; ec = mitral annular tissue velocity; LVAD = left ventricular assist device; Pts = patients; SLAM = slope 
of the anterior mitral valve leaflet 
 
*On the basis of paired t test 
 
Values are expressed as mean r SD. P <0.05 was considered statistically significant.
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Fig. 5  M-mode transthoracic echocardiograms  
of the mitral valve in a patient with congestive 
heart failure symptoms show A) a view before 
left ventricular assist device implantation with B) an 
associated slope of the anterior mitral valve leaflet (SLAM) 
of 5.3 cm/s; and C) a view after device implantation 
with D) an associated SLAM of 19.3 cm/s. E) M-mode 
image shows a SLAM of 11.9 cm/s in the same patient 
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diographic measurement that in paired analyses appears 
to correlate with LV unloading by an LVAD and is an 
indicator of heart-failure clinical status both in native 
heart failure and in patients with an implanted CF-
LVAD.
 Our data suggest an inverse relationship between the 
SLAM and LV f illing pressures in LVAD-supported 
and -unsupported hearts. The physiologic mechanisms 
underlying this observation necessitate further investi-
gation; however, we currently hypothesize the following 
potentially contributory mechanisms. First, concomi-
tant diastolic and moderate-to-severe systolic dysfunc-
tion (LVEF <0.35) has been shown in patients to result 
in an increased LV end-diastolic pressure (LVEDP).10 In 
those patients who have an elevated left atrial pressure, a 
longer time would then be required for the ventricle to 
generate a pressure greater than that in the atrium and 
would thereby affect mitral valve closure. Investigators 
who conducted prior invasive and hemodynamic studies 
have reported a qualitatively prolonged transmitral flow 
and delayed closure of the mitral valve in patients with 
an elevated LVEDP, evidenced with use of M-mode 
echocardiography.21 Poor LV contractile function cor-
relates with a decreased rate of developed LV pressure 
during systole (dP/dt) through the increase in time for 
the ventricle to produce the Doppler jet of mitral re-
gurgitation.22 Similar to SLAM, dP/dt has been shown 






























Fig. 6  A) Graph shows comparisons in slope of the anterior 
mitral valve leaflet (SLAM) in 42 patients before left ventricular 
assist device (LVAD) insertion, in the same 42 patients after 
LVAD insertion, and in 60 different, randomly selected patients 
without an LVAD but with left ventricular ejection fraction 
(LVEF) <0.35. P <0.05 was considered statistically significant. 
B) Receiver operating characteristic analysis indicates that the 
SLAM can distinguish patients in end-stage heart failure and 
before LVAD implantation from randomly selected patients with 
an LVEF <0.35 at an area under the curve (AUC) of 0.7742 (95% 
confidence interval, 0.6853–0.8631).
TABLE VI. Sensitivity and Specificity Analysis of SLAM in 
Predicting Pre-LVAD Status versus LVEF <0.35
    Youden 
SLAM Cutpoint* Sensitivity Specificity Index
 5 0.2143 0.9833 0.1976
 6 0.3571 0.9667 0.3238
 7 0.5238 0.8 0.3238
 8 0.619 0.65 0.269
 9 0.7857 0.6 0.3857
 10 0.881 0.55 0.431
 11 0.9286 0.4833 0.4119
 12 0.9286 0.4333 0.3619
 13 0.9762 0.35 0.3262
 14 1 0.25 0.25
 15 1 0.2167 0.2167
 16 1 0.15 0.15
 17 1 0.15 0.15
 18 1 0.1 0.1
 19 1 0.0667 0.0667
 20 1 0.05 0.05
 21 1 0.05 0.05
 22 1 0.0333 0.0333
 23 1 0.0333 0.0333
 24 1 0.0333 0.0333
 25 1 0.0167 0.0167
 
LVAD = left ventricular assist device; LVEF = left ventricular ejec-
tion fraction; SLAM = slope of the anterior mitral valve leaflet 
 
* The cutpoint of 10 cm/s distinguished random patients with 
LVEF <0.35 from those in end-stage congestive heart failure 
(pre-LVAD) with an 88% sensitivity and a 55% specificity.
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tion.8 Regardless of the cause of cardiomyopathy, a 
high LVEDP and weak contractile function culminate 
in ineffective unloading, which is consistent with the 
delayed-closure physiology of the mitral valve observed 
in M-mode echocardiography, and which in this study 
was quantified as the SLAM.
 In unsupported patients with LVEF <0.35, there was 
a correlation between SLAM and E/ec measurements, 
and E/ec is well validated and routinely used in this pop-
ulation to correlate closely with LV filling pressures.5,23 
In addition, our data indicate that SLAM is able to 
identify, with good sensitivity and specificity, patients 
with a depressed LVEF who are sicker. A SLAM cut-
point value of <10 cm/s differentiates patients with 
end-stage CHF who are clinically determined to need 
LVAD support from a random cohort of patients with 
LVEF <0.35. Although all echocardiographic values 
should be analyzed within the clinical context of each 
individual patient, a SLAM <10 cm/s or an appreciable 
decrease in SLAM might trigger a change in medical 
therapy or accelerate referral for advanced heart-failure 
therapies.
 The SLAM method appears to have a unique capac-
ity to provide a metric of ventricular unloading in an 
LVAD-supported population. The average SLAM of 
patients with end-stage CHF doubled after LVAD im-
plantation—and, in a limited subgroup analysis within 
our data set, appeared to detect clinical deterioration 
sensitively in patients with LVADs who were readmit-
ted for CHF symptoms. The possible causes of CHF 
exacerbations in an LVAD population are varied and 
might include inadequate rotor speed and unloading 
of the LV, or worsening of native heart failure. Each 
of these complications would lead to a decrease in the 
left atrial and LV gradients and prolong the closure of 
the mitral valve. Regular evaluation of the SLAM after 
LVAD implantation might provide the treating physi-
cian with a sensitive, noninvasive tool for rapidly evalu-
ating the adequacy of LV unloading in these patients 
who have complications. In addition, we anticipate that 
SLAM might be used in future studies to adjust the 
LVAD for clinical optimization and for long-term pa-
tient monitoring. Prospective analyses at fixed imaging 
intervals after LVAD implantation will result in more 
rigorous future validation of the SLAM method.
Study Limitations
This study has several important limitations. First, it 
is a single-institution, retrospective study. Because the 
SLAM was not prospectively collected, many patients 
had insuff icient echocardiographic images or cardiac 
cycles from which to obtain the SLAM; and in some 
cases, M-mode TTE of the mitral valve was not avail-
able. Furthermore, echocardiograms were obtained at 
varying intervals postoperatively, and we were unable 
to categorize them into consistent time-intervals for a 
thorough longitudinal study. We did not evaluate the 
correlation between the SLAM and aortic valve opening 
in LVAD patients, because aortic valve opening is also 
variable, with an unknown mathematical correlation to 
unloading.20,24 In addition, SLAM cannot be applied 
to patients who have atrial fibrillation or flutter, a me-
chanical mitral valve, or poor 2D TTE windows that 
preclude seeing the mitral valve in M mode.
Conclusion
We introduce the SLAM as a promising, novel, M-
mode echocardiographic method of evaluating LV fill-
ing pressures, and we provide evidence to suggest that 
it remains valid in patients with a CF-LVAD. This 
method adds to an expanding panel of echocardio-
graphic methods that are used to evaluate LV unloading 
in LVAD recipients. Further echocardiographic studies 
are needed to determine the usefulness of SLAM in 
other patient populations and to establish a time course 
of dynamic changes of echocardiographic values within 
the post-implantation LVAD population toward LVAD 
optimization, clinical status, and outcomes.
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